致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 FF301 第 2 頁 共 11 頁 v 1.1.1 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | ...

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

截至2025年8月29日收盘，昭衍新药（603127）报收于31.39元，较上周的31.2元上涨0.61%。本周，昭 衍新药8月27日盘中最高价报33.68元。8月28日盘中最低价报29.0元。昭衍新药当前最新总市值235.26亿 元，在医疗服务板块市值排名6/50，在两市A股市值排名802/5152。 本周关注点 业绩披露要点 昭衍新药2025年中报显示，公司主营收入6.69亿元，同比下降21.28%；归母净利润6093.24万元，同比 上升135.9%；扣非净利润2305.22万元，同比上升111.62%；其中2025年第二季度，公司单季度主营收入 3.81亿元，同比下降27.32%；单季度归母净利润1981.29万元，同比下降80.67%；单季度扣非净利 润-261.04万元，同比下降103.17%；负债率14.44%，投资收益1313.53万元，财务费用-3741.81万元，毛 利率24.03%。 公司公告汇总 北京昭衍新药研究中心股份有限公司2025年半年度报告摘要显示，公司总资产为9473462262.30元，较 上年度末增长0.82%；归属于上市公司股东的净资产为8104696831.48元，较 ...

又一家上市公司做LP。 近日，上市公司昭衍新药发布公告称，公司或其指定子公司拟与深圳市倚锋投资管理企业（有限合伙）（以下简称"倚锋资本"）、深圳市倚锋明 远科技有限公司（以下简称"倚锋明远"）及各相关方签署《合伙协议》，发起设立深圳市倚锋光明科学城种子基金（有限合伙）。 文：韦亚军 | | | 92.18 | | 6.93 6 | | | | --- | --- | --- | --- | --- | --- | --- | | | 20.26 | 124 | 20.25 | 20.26 136.8万 | | | | | 4.45 | 0.39 | 4.45 | 4.46 218.5万 | | | | 194 | 33.35 | 1.57 | 33.35 | 33.36 610545 | | | | 1.71 | 4.16 | 0.07 | 4.16 | 4.17 843.4万 | | | | 4.61 | 37.24 | 1.64 | 37.24 | 37.25 208493 | | | | 2.58 | 13.93 | 0.35 | 13.93 | 13.94 476739 | 2048 | -0.13 ...

Core Viewpoint - The Hong Kong pharmaceutical outsourcing sector experienced a significant rally, with multiple companies seeing substantial stock price increases on August 29. Group 1: Stock Performance - Vyaire Biotech (01873.HK) surged over 17% [2] - WuXi Biologics (02269.HK) rose more than 8.5% [2] - Zai Lab (06127.HK) and WuXi AppTec (02359.HK) both increased by over 7% [2] - Kelun Pharmaceutical (06821.HK) and Hangzhou Tigermed Consulting (03759.HK) both saw gains exceeding 4% [2]

Group 1 - The company, Beijing Zhaoyan New Drug Research Center Co., Ltd., has approved an investment of up to 20 million RMB to participate in the establishment of the Huaxia Zhiyuan Venture Capital Fund [1][2] - The fund is managed by Huaxia Equity Investment Fund Management (Beijing) Co., Ltd., which serves as the general partner and fund manager [1] - The fund has completed the private investment fund registration with the Asset Management Association of China and obtained the Private Investment Fund Registration Certificate on August 27, 2025 [3] Group 2 - The fund's name is Huaxia Zhiyuan Venture Capital Fund (Beijing) Partnership (Limited Partnership) [3] - The custodian of the fund is Ping An Bank Co., Ltd. [3] - The registration code for the fund is SASP05 [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年8月28日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

证券简称：昭衍新药 证券代码：603127 公告编号：2025-037 北京昭衍新药研究中心股份有限公司 关于与专业投资机构合作参与投资设立基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、与专业投资机构合作参与投资设立产业基金情况概述 北京昭衍新药研究中心股份有限公司（以下简称"昭衍新药"、"公司"）于 2024 年 12 月 20 日召开第四届董事会第十一次会议，审议通过了《关于公司与专业投 资机构合作参与投资设立基金的议案》，同意公司或指定子公司以不超过 2,000 万人民币投资参与华夏致远创业投资基金（北京）合伙企业（有限合伙）（以下 简称"本基金"、"合伙企业"）的发起设立。华夏股权投资基金管理（北京） 有限公司为本基金的普通合伙人、执行事务合伙人，并担任本基金的基金管理人。 具体内容详见公司于2024年12月21日在上海证券交易所网站（www.sse.com.cn） 及指定信息披露媒体《上海证券报》披露的《昭衍新药关于与专业投资机构合作 参与投资设立基金的公告》（公告编号：2024-060）。 2 ...

Core Viewpoint - The pharmaceutical research and development outsourcing company, Zhaoyan New Drug, reported a significant decline in revenue for the first half of 2025, but managed to turn a profit in net income and net profit after deducting non-recurring items, indicating a potential recovery despite ongoing challenges in its laboratory services business [1][3][6]. Financial Performance - In the first half of 2025, Zhaoyan New Drug achieved revenue of approximately 669 million yuan, a year-on-year decrease of 21.28% [1]. - The company reported a net profit attributable to shareholders of 60.93 million yuan and a net profit of 23.05 million yuan after deducting non-recurring items, marking a turnaround from previous losses [1]. - The laboratory services business contributed a net profit of -97.18 million yuan, a decline of 537.54% compared to the previous year, indicating ongoing price competition in this segment [3]. Business Structure and Market Position - Zhaoyan New Drug is recognized as a leader in non-clinical safety evaluation services within the CRO (Contract Research Organization) sector, primarily focusing on preclinical drug development [5]. - The company has faced challenges due to significant losses related to biological assets, particularly concerning the management of laboratory animals, but these pressures appear to be easing [5][6]. Historical Context and Future Outlook - The company experienced a peak in performance in 2022, coinciding with the end of a significant growth period in the domestic biopharmaceutical industry [9][11]. - The sales net profit margin for Zhaoyan New Drug was 47.32% in 2022, but has since dropped to 16.48% in 2023 and 3.46% in 2024, with a mere 9.11% in the first half of 2025, indicating a need for substantial improvement in profitability [11].